NCT02447276

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 421 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the effectiveness of REGN475 compared to placebo in participants with pain due to osteoarthritis (OA) of the knee or hip and a history of inadequate joint pain relief or intolerance to current analgesic therapy.

Conditions

• Osteoarthritis, Knee
• Osteoarthritis, Hip

Interventions

Type	Name	Description
DRUG	REGN475
DRUG	Placebo

Timeline

• Start date: 2015-05-01
• Primary completion: 2016-03-01
• Completion: 2016-11-01
• First posted: 2015-05-18
• Last updated: 2017-03-27

Locations

72 sites across 1 country: United States